Valneva reports 94% five‑year antibody persistence for chikungunya vaccine IXCHIQ
Valneva SE said that 94% of the 221 healthy adults in its long‑term study still had neutralising antibody titres above the seroresponse threshold five years after a single dose of IXCHIQ. The durability was similar in participants aged 65 and older and those aged 18‑64. The company will keep monitoring the cohort for up to ten years and is expanding real‑world evidence programmes, including a large vaccination pilot in Brazil.
Why it matters
The data reinforce IXCHIQ’s long‑term value proposition, which could support continued sales and potential market expansion, especially in regions where chikungunya outbreaks are unpredictable. Investors may view the durability evidence as a catalyst for the stock, as reflected in recent price gains.
Key facts
- 194% of the 221 evaluable adults maintained neutralising antibody titres above the seroresponse threshold at Year 5. sina.com.hk
- 2Antibody persistence in adults aged 65 years and older was comparable to that in adults aged 18‑64 years. sina.com.hk
- 3The study participants will be followed for up to ten years to further characterise long‑term immune durability. sina.com.hk
- 4Valneva is conducting a post‑marketing pilot vaccination strategy in Brazil that vaccinated nearly 80,000 adults between February and October 2026. sina.com.hk
- 5IXCHIQ sales were €4.4 million in the first half of 2026, compared with €7.5 million in the first half of 2025. rttnews.com
Summary written by AlphAI AI Desk from 6 of 6 sources. Not investment advice. Figures are as stated by the linked sources.